Despite management's optimistic guidance for 2026, the significant revenue decline in 2025 suggests ongoing pricing pressures that may be difficult to overcome. Traders should monitor whether the company can achieve its ambitious 2026 EBITDA target of over $300 million given the revenue headwinds. The increased cash position provides some buffer, but the fundamental trend remains negative.
Price Chart
Executive Summary
Ironwood Pharmaceuticals reported full-year 2025 revenue of $296 million, down from $351.4 million in 2024, with GAAP net income of $24 million and adjusted EBITDA of $138 million. Despite declining revenue and profits, the company reiterated strong 2026 guidance with expected total revenue of $450-$475 million and adjusted EBITDA exceeding $300 million, driven by improved net pricing and continued expense discipline. LINZESS demand grew 11% year-over-year in 2025.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $296.2 million, down 15.7% from $351.4 million in 2024
- GAAP net income was $24 million in 2025, up from $0.9 million in 2024, but driven by one-time factors
- Adjusted EBITDA was $138.1 million in 2025, up slightly from $129.4 million in 2024
- LINZESS U.S. net sales declined 6% to $864.5 million in 2025
- Company reiterates 2026 guidance of $450-$475 million revenue and >$300 million adjusted EBITDA
- Cash and cash equivalents increased to $215.5 million from $88.6 million in 2024
Financial Impact
Revenue decreased by $55.3 million (15.7%) year-over-year, with LINZESS U.S. net sales down 6%
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| LINZESS | $864.5M | -5.6% |
Risk Factors
- Continued pricing pressure on LINZESS from Medicare Part D redesign
- Failure to achieve 2026 guidance targets despite reiteration
- Dependence on successful development of apraglutide to drive future growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-019405 |
| Document: tm267094d1_8k.htm | 0001104659-26-019405 |
| Document: 0001104659-26-019405-index-headers.html | 0001104659-26-019405 |
| Document: 0001104659-26-019405-index.html | 0001104659-26-019405 |
| Document: 0001104659-26-019405.txt | 0001104659-26-019405 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $4.26 $4.29 | ▲ +0.70% | ▲ +0.10% | $3.64 (−14.55%) |
May 13, 2026 20w ago | 8-K | $3.68 $3.63 | ▼ −1.36% | ▼ −0.75% | $3.64 (−1.09%) |
May 7, 2026 21w ago | 8-K | $4.17 $3.24 | ▼ −22.30% | ▼ −25.44% | $3.64 (−12.71%) |
Feb 25, 2026 31w ago | 8-K | $3.36 $3.19 | ▲ +5.06% | ▼ −0.18% | $3.64 (−8.33%) |
Feb 23, 2026 31w ago | Insider Cluster | $3.75 $3.29 | ▲ +12.27% | ▲ +8.32% | $3.64 (+2.93%) |
Feb 23, 2026 31w ago | Insider Cluster | $3.75 $3.29 | ▲ +12.27% | ▲ +8.32% | $3.64 (+2.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access